Gemcitabine et cancers bronchiques non à petites cellules

Stéphane Vignot; Benjamin Besse

doi:10.1684/bdc.2007.0370

Gemcitabine et cancers bronchiques non à petites cellules

Translated title of the contribution: Gemcitabine and non small-cell lung cancer

Stéphane Vignot, Benjamin Besse

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

Questions raised during gemcitabine development reflect non small-cell lung cancer (NSCLC) history during last 10 years. Third generation therapies (gemcitabine, vinorelbine and taxanes) combined with platinium compounds are now to be prescribed in almost all clinical situations, from surgically removed tumors to metastatic diseases. The 30 % response rate usually reported in advanced disease (with a median survival of 10 months) has to be improved and a more global approach is nowadays mandatory, including targeted agents. This review sum-up the clinical situations in which gemcitabine can be prescribed (advanced disease), or shall be prescribed (adjuvant setting, combination with anti-angiogenic agent or EGFR inhibitors), and highlight opening questions.

Translated title of the contribution	Gemcitabine and non small-cell lung cancer
Original language	French
Pages (from-to)	S95-S103
Journal	Bulletin du Cancer
Volume	94
Issue number	SPEC. ISS.
DOIs	https://doi.org/10.1684/bdc.2007.0370
Publication status	Published - 1 Jun 2007

Access to Document

10.1684/bdc.2007.0370

Cite this

@article{e295af19bc2344edb7f903da56704269,

title = "Gemcitabine et cancers bronchiques non {\`a} petites cellules",

abstract = "Questions raised during gemcitabine development reflect non small-cell lung cancer (NSCLC) history during last 10 years. Third generation therapies (gemcitabine, vinorelbine and taxanes) combined with platinium compounds are now to be prescribed in almost all clinical situations, from surgically removed tumors to metastatic diseases. The 30 % response rate usually reported in advanced disease (with a median survival of 10 months) has to be improved and a more global approach is nowadays mandatory, including targeted agents. This review sum-up the clinical situations in which gemcitabine can be prescribed (advanced disease), or shall be prescribed (adjuvant setting, combination with anti-angiogenic agent or EGFR inhibitors), and highlight opening questions.",

keywords = "Chemotherapy, Gemcitabine, Non small cell lung cancer",

author = "St{\'e}phane Vignot and Benjamin Besse",

year = "2007",

month = jun,

day = "1",

doi = "10.1684/bdc.2007.0370",

language = "Fran{\c c}ais",

volume = "94",

pages = "S95--S103",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "SPEC. ISS.",

}

TY - JOUR

T1 - Gemcitabine et cancers bronchiques non à petites cellules

AU - Vignot, Stéphane

AU - Besse, Benjamin

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Questions raised during gemcitabine development reflect non small-cell lung cancer (NSCLC) history during last 10 years. Third generation therapies (gemcitabine, vinorelbine and taxanes) combined with platinium compounds are now to be prescribed in almost all clinical situations, from surgically removed tumors to metastatic diseases. The 30 % response rate usually reported in advanced disease (with a median survival of 10 months) has to be improved and a more global approach is nowadays mandatory, including targeted agents. This review sum-up the clinical situations in which gemcitabine can be prescribed (advanced disease), or shall be prescribed (adjuvant setting, combination with anti-angiogenic agent or EGFR inhibitors), and highlight opening questions.

AB - Questions raised during gemcitabine development reflect non small-cell lung cancer (NSCLC) history during last 10 years. Third generation therapies (gemcitabine, vinorelbine and taxanes) combined with platinium compounds are now to be prescribed in almost all clinical situations, from surgically removed tumors to metastatic diseases. The 30 % response rate usually reported in advanced disease (with a median survival of 10 months) has to be improved and a more global approach is nowadays mandatory, including targeted agents. This review sum-up the clinical situations in which gemcitabine can be prescribed (advanced disease), or shall be prescribed (adjuvant setting, combination with anti-angiogenic agent or EGFR inhibitors), and highlight opening questions.

KW - Chemotherapy

KW - Gemcitabine

KW - Non small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=34547789857&partnerID=8YFLogxK

U2 - 10.1684/bdc.2007.0370

DO - 10.1684/bdc.2007.0370

M3 - Article 'review'

C2 - 17845978

AN - SCOPUS:34547789857

SN - 0007-4551

VL - 94

SP - S95-S103

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - SPEC. ISS.

ER -

Gemcitabine et cancers bronchiques non à petites cellules

Abstract

Access to Document

Other files and links

Cite this